Methods of limiting apoptosis of cells
First Claim
Patent Images
1. A method for limiting apoptosis of a mammalian cell population, the method comprising contacting the cell population with an effective amount of an apoptotic limiting compound selected from the group of ursodeoxycholic acid, a salt thereof, an analog thereof, and a combination thereof, wherein the apoptosis is induced by a nonmembrane damaging agent.
0 Assignments
0 Petitions
Accused Products
Abstract
Methods for limiting apoptosis in a cell population by contacting such cells with a hydrophilic bile acid, such as ursodeoxycholic acid (UDCA), salts thereof, and analogs thereof (e.g., glyco- and tauro-ursodeoxycholic acid).
-
Citations
83 Claims
- 1. A method for limiting apoptosis of a mammalian cell population, the method comprising contacting the cell population with an effective amount of an apoptotic limiting compound selected from the group of ursodeoxycholic acid, a salt thereof, an analog thereof, and a combination thereof, wherein the apoptosis is induced by a nonmembrane damaging agent.
-
12. A method for limiting apoptosis of a mammalian cell population, the method comprising contacting the cell population with an effective amount of an apoptotic limiting compound selected from the group of ursodeoxycholic acid, a salt thereof, an analog thereof, and a combination thereof, wherein the apoptosis is induced by ethanol.
-
13. A method for limiting apoptosis of a human cell population, the method comprising contacting the cell population with an effective amount of an apoptotic limiting compound selected from the group of hydrophilic bile acid, a salt thereof, an analog thereof, and a combination thereof, wherein the apoptosis is induced by a hydrophobic bile acid.
-
14. A method for limiting apoptosis of a mammalian cell population, the method comprising contacting the cell population with an effective amount of an apoptotic limiting compound selected from the group of hydrophilic bile acid, a salt thereof, an analog thereof, and a combination thereof, wherein the apoptosis is induced by TGF-β
- 1, anti-Fas antibody, okadaic acid, or unconjugated bilirubin.
- 15. A method for inhibiting apoptosis associated with a nonliver disease in vivo, the method comprising administering ursodeoxycholic acid, a salt thereof, an analog thereof, or a combination thereof.
-
17. A method of reducing expression of c-myc in a cell, the method comprising contacting the cell with an effective amount of ursodeoxycholic acid, a salt thereof, an analog thereof, or a combination thereof.
-
18. A method of increasing levels of Bcl-XL in a cell, the method comprising contacting the cell with an effective amount of ursodeoxycholic acid, a salt thereof, an analog thereof, or a combination thereof.
-
19. A method of inhibiting Bax translocation from the cytoplasm of a cell to a mitochondrial membrane, the method comprising contacting the cell with an effective amount of ursodeoxycholic acid, a salt thereof, an analog thereof, or a combination thereof.
- 20. A method for limiting apoptosis of a mammalian cell population, the method comprising contacting the cell population with an effective amount of an apoptotic limiting compound selected from the group of ursodeoxycholic acid, a salt thereof, an analog thereof, and a combination thereof, wherein the apoptosis is induced by a membrane damaging agent selected from the group consisting of unconjugated bilirubin, conjugated bilirubin, and a combination thereof.
- 30. A method of treating a patient with a neurodegenerative disease, the method comprising administering to a patient ursodeoxycholic acid, a salt thereof, an analog thereof, or a combination thereof.
- 40. A method of treating a patient with a stroke injury, the method comprising administering to the patient ursodeoxycholic acid, a salt thereof, an analog thereof, or a combination thereof.
- 47. A method of treating a patient with an autoimmune disease, the method comprising administering to the patient ursodeoxycholic acid, a salt thereof, an analog thereof, or a combination thereof.
- 57. A method of treating a patient with a cardiovascular disease or a cerebrovascular disease, the method comprising administering to the patient ursodeoxycholic acid, a salt thereof, an analog thereof, or a combination thereof.
- 65. A method of treating a patient prophylactically for an autoimmune disease, a neurodegenerative disease, a cardiovascular disease, or a cerebrovascular disease, the method comprising administering to the patient ursodeoxycholic acid, a salt thereof, an analog thereof, or a combination thereof.
- 75. A method of limiting apoptosis of a mammalian cell population, the method comprising contacting the cell population with an effective amount of an apoptotic limiting compound that modulates mitochondrial membrane perturbation.
- 79. A method of limiting apoptosis of a mammalian cell population, the method comprising contacting the cell population with an effective amount of an apoptotic limiting compound that modulates mitochondrial transmembrane potential and reactive oxygen species production.
-
83. A method of inhibiting Bax translocation from the cytoplasm of a cell to a mitochondrial membrane;
- the method comprising contacting the cell with an effective amount of a compound that limits apoptosis through a mitochondrial membrane.
Specification